Geneva: The World Health Organization (WHO) accepted the recommendation from the Solidarity Trial’s International Steering Committee on Saturday, to discontinue the trials of hydroxychloroquine (HCQ) and lopinavir/ritonavir arms.
According to a press release, citing little or no reduction in the mortality rate of the hospitalised COVID-19 patients, WHO reportedly said, the decision was in light of the evidence from the Solidarity Trial’s interim results.
“These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized Covid-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect,” Xinhua reported WHO’s release.
The Solidarity Trial was established by WHO to find an effective COVID-19 treatment for patients already admitted to hospitals.
